Harsco Corp. (HSC) Drops 5.32% on February 02

Equities Staff |

Harsco Corp. (HSC) was one of the Russell 2000's biggest losers for Tuesday February 02 as the stock slid 5.32% to $6.14, a loss of $-0.345 per share. Starting at an opening price of $6.23 a share, the stock traded between $6.05 and $6.30 over the course of the trading day. Volume was 376,546 shares over 2,596 trades, against an average daily volume of 834,264 shares and a total float of 80.09 million.

The losses send Harsco Corp. down to a market cap of $491.38 million. In the last year, Harsco Corp. has traded between $18.00 and $5.28, and its 50-day SMA is currently $7.98 and 200-day SMA is $11.77.

Harsco Corp is engaged in providing industrial services & engineered products to various industries. It has three reportable segments: Harsco Metals & Minerals, Harsco Industrial and Harsco Rail. It has locations in approximately 35 countries.

Harsco Corp. is based out of Camp Hill, PA and has some 12,200 employees. Its CEO is F. Nicholas Grasberger.

For a complete fundamental analysis analysis of Harsco Corp., check out Equities.com’s Stock Valuation Analysis report for HSC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…